Riociguat

5 trials 1 recruiting CCardiology

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

3 Sponsors

6 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 1 Phase II: 2 Phase III/IV: 1 Phase IV: 1

Indications tested

Pulmonary arterial hypertension 1

Sponsors using this IMP

Bayer AG 2 Thoraxklinik Heidelberg gGmbH 2 Amsterdam UMC Stichting 1

All trials

5 total

STOP-RIO: A randomized controlled non-inferiority trial to test the safety of discontinuation of riociguat after balloon pulmonary angioplas… Recruiting

2024-519225-38-00 Phase III/IV 1 country Amsterdam UMC Stichting
Riociguat for treatment of PAH in children from 6 to less than 18 years old Ended

2023-503536-40-00 Phase III 2 countries Bayer AG
Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension… Ended

2023-509695-42-00 Phase II 4 countries Thoraxklinik Heidelberg gGmbH
An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hyp… Ended

2023-509696-17-00 Phase IV 1 country Thoraxklinik Heidelberg gGmbH
Placebo-controlled, multi-center study to evaluate catheter derived tests of Riociguat (BAY 63-2521) as well as safety and blood samples in … Ended

2023-507001-34-00 Phase II 3 countries Bayer AG

Showing 1–5 of 5 trials

← All drugs A–Z